RJA
EVFM

Raymond James & Associates’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Raymond James & Associates’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,217
Closed -$13K – 4343
2021
Q3 		$13K Buy
1,217
+200
+20% +$2.51K ﹤0.01% 4045
2021
Q2 		$17K Buy
+1,017
New +$19.3K ﹤0.01% 3998

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Raymond James & Associates's EVFM Position: Q4 2021 in Review

Raymond James & Associates sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 1,217 shares — an estimated $13K sold.

Raymond James & Associates first reported a position in EVFM in Q2 2021 and held it in 2 quarters. The position peaked at $17K in Q2 2021. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

  • Raymond James & Associates reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 1,217 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $13K.
  • Raymond James & Associates first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Raymond James & Associates's Evofem Biosciences, Inc. Common Stock position peaked at $17K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.